Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation

Blood

Volumn 91, Issue 8, 1998, Pages 2679-2688

  Dhodapkar, Madhav V ^a   Abe, Etsuko ^a   Theus, Allison ^a   Lacy, Marie ^a   Langford, J Kevin ^a   Barlogie, Bart ^a   Sanderson, Ralph D ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Department of Pathology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOHEPARAN SULFATE; SYNDECAN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PARALYSIS; PATHOLOGY; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH;

EID: 0032523191     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.2679.2679_2679_2688     Document Type: Article

References (43)

1. Barlogie B: Plasma cell myeloma, in Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds): William's Textbook of Hematology. New York, NY, McGraw Hill, 1995, p 1109
2. Klein B: Cytokines, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin Hematol 32:4, 1995
3. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KC: Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 90:279, 1997
4. Herrmann F, Andreeff M, Gruss HJ, Brach MA, Lubbert M, Mertelsmann R: Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 78:2070, 1991
5. Bataille R, Manolagas SC, Berenson JR: Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 11:349, 1997
6. Bataille R, Chappard D, Marcelli C, Dessauw P, Sang J, Baldet P, Alexandre C: Mechanism of bone destruction in multiple myeloma. The importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7:1909, 1989
7. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC: Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688, 1991
8. Mundy GR, Raisz LG, Cooper RA, Schecter GP, Salmon SE: Evidence for secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041, 1974
9. Barille S, Collette M, Bataille R, Amiot M: Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 86:3151, 1995
10. Carey DJ: Syndecans: Multifunctional cell-surface co-receptors. Biochem J 327:1, 1997
11. Sanderson RD, Lalor P, Bernfield M: B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1:27, 1989
12. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD: Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81:767, 1993
13. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM: A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94:318, 1996
14. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A: Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88:3998, 1996
15. Sanderson RD, Sneed TB, Young LA, Sullivan GL, Lander AD: Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by the integral membrane proteoglycan, syndecan. J Immunol 148: 3902, 1992
16. Liebersbach BF, Sanderson RD: Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269:20013, 1994
17. Stanley MJ, Liebersbach BF, Liu W, Anhalt DJ, Sanderson RD: Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J Biol Chem 270:5077, 1995
18. Jalkanen M, Nguyen H, Rapraeger A, Kurn N, Bernfield M: Heparan sulfate proteoglycans from mouse mammary epithelial cells: Localization on the cell surface with a monoclonal antibody. J Cell Biol 101:976, 1985
19. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC: Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 97:1732, 1996
20. Yamate T, Mocharla H, Taguchi Y, Igietseme JU, Manolagas SC, Abe E: Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: Demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy. Endocrinology 138:3047, 1997
21. Bernfield M, Hooper KC: Possible regulation of FGF activity by syndecan, an integral membrane heparan sulfate proteoglycan. Ann NY Acad Sci 638:182, 1991
22. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84:3063, 1994
23. Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ, Vitetta ES: Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 53:1392, 1993
24. Alsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR, Roodman GD: Development of an in vivo model of human multiple myeloma bone disease. Blood 87:1495, 1996
25. Ruoslahti E, Yamaguchi Y: Proteoglycans as modulators of growth factor activities. Cell 64:867, 1991
26. Smith KGC, Hewitson TD, Nossal GJV, Tarlinton DM: The phenotype and fate of antibody forming cells of the splenic foci. Eur J Immunol 26:444, 1996
27. Mali M, Andtfolk H, Miettinen HM, Jalkanen M: Suppression of tumor cell growth by syndecan-1 ectodomain. J Biol Chem 269:27795, 1994
28. Numa F, Hirabayashi K, Tsunaga N, Kato H, O'Rourke K, Shao H, Stechmann-Lebakken C, Varani J, Rapraeger A, Dixit VM: Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293T cells. Cancer Res 55:4676, 1995
29. Mathiak M, Yenisey C, Grant DS, Sharma B, lozzo RV: A role for pertecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res 57:2130, 1997
30. De Luca A, Santra M, Baldi A, Giordano A, Iozzo R: Decorin induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin dependant kinases. J Biol Chem 271:18691, 1996
31. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD: Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 99:368, 1997
32. Khoory RN, Nishheim ME, Bowie EJW, Mann KG: Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest 66:666, 1981
33. Subramanian SV, Fitzgerald ML, Bernfield M: Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 272:14713, 1997
34. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P: The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 75:254, 1996
35. Shaughnessy SG, Young E, Deschamps P, Hirsh J: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368, 1995
36. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG: A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 89:3236, 1997
37. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsburn M: Growth factors in bone matrix: Isolation of multiple types by affinity chromatography on heparin-sepharose. J Biol Chem 261:12665, 1986
38. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K: Isolation of a novel cytokine from human firoblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137, 1997
39. Thesleff I, Jalkanen M, Vainio S, Bernfield M: Cell surface proteoglycan expression correlates with epithelial-mesenchymal interaction during tooth morphogenesis. Dev Biol 129:565, 1988
40. Chen Y, Bei M, Woo I. Satokata I, Maas R: Msx1 controls inductive signaling in mammalian tooth morphogenesis. Development 122:3035, 1996
41. Carbone A, Gloghini A, Gattei V, Degan M, Improta S, Aldinucci D, Canzonieri V, Perin T, Volpe R, Gaidano G, Zagonel V, Pinto A: Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 89:3787, 1997
42. Gaidano G, Gloghini A, Gattei V, Rossi MF, Cilia AM, Godeas C, Degan M, Perin T, Canzonieri V, Aldinucci D, Saglio G, Carbone A, Pinto A: Association of Kaposi's sarcoma associated herpesvirus-positive primary effusion lymphoma with expression of the CD 138/syndecan-1 antigen. Blood 90:4894, 1997
43. Inki P, Jalkanen M: The role of syndecan-1 in malignancies. Ann Med 28:63, 1996